Pioglitazone might prevent the progression of slowly progressive type 1 diabetes

Internal Medicine

Volumn 48, Issue 12, 2009, Pages 1037-1039

  Kawano, Yoshinaga ^a,b   Irie, Junichiro ^a,b   Nakatani, Hiroshi ^a,b   Yamada, Satoru ^a,b  

^a KITASATO INSTITUTE HOSPITAL   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti GAD antibody; Pioglitazone; PPAR ; Slowly progressive type 1 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HLA ANTIGEN; PIOGLITAZONE;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; ORAL GLUCOSE TOLERANCE TEST; SLOWLY PROGRESSIVE INSULIN DEPENDENT DIABETES MELLITUS; URETER STONE;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 67650078962     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1990     Document Type: Article

References (13)

1. Kobayashi T, Itho T, Kosaka K, Sato K, Tsuji K. Time course of islet cell antibodies and B-cell function in non-insulin-dependent stage of type 1 diabetes. Diabetes 36: 510-517, 1987.
2. Zimmet PZ, Elliott RB, Mackay IR, et al. Autoantibodies to glutamic acid decarboxylase and insulin in islet cell antibody positive pre-symptomatic type 1 diabetes mellitus; frequency and segregation by age and gender. Diabet Med 11: 866-871, 1994.
3. Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93: 2115-2121, 2008.
4. Aston-Mourney K, Proietto J, Morahan G, Andrikopoulos S. Too much of a good thing; why it is bad to stimulate the beta cell to secrete insulin. Diabetologia 51: 540-545, 2008.
5. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28: 551-558, 2007.
6. Niino M, Iwabuchi K, Kikuchi S, et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by agonist of peroxisome proliferator-activated receptor gamma. J Neuroimmunol 116: 40-48, 2001.
7. Fukuda M, Ikegami H, Fu J, et al. CS-045, a new oral antidiabetic agent, prevents the development of cyclophosphamide-induced diabetes in NOD mice. J Jpn Diab Soc 37: 127-130, 1994 (Abstract in English).
8. Beales PE, Liddi R, Giorgini AE, et al. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur J Pharmacol 357: 221-225, 1998.
9. Ogawa J, Takahashi S, Fujiwara T, et al. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci 65: 1287-1296, 1999.
10. Augstein P, Dunger A, Heinke P, et al. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun 304: 378-384, 2003.
11. Takamura T, Ando H, Nagai Y, Yamashita H, Nohara E, Kobayashi K. Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res Clin Pract 44: 107-114, 1999.
12. Beales PE, Pozzolli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev 18: 114-117, 2002.
13. Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 21: 203-208, 2005.